Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $183.12. The company's market cap stands at 26.87B, with a P/E ratio of 20.86.
As of 2026-04-01, Biogen(BIIB) stock has fluctuated between $181.71 and $186.31. The current price stands at $183.12, placing the stock +0.8% above today's low and -1.7% off the high.
The Biogen(BIIB)'s current trading volume is 693.93K, compared to an average daily volume of 1.16M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $110.04.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $110.04.
BIIB News
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Oppenheimer raised the firm’s price target on Biogen to $275 from $250 and keeps an Outperform rating on the shares. The firm believes Biogen’s (BIIB) acquisiti...
Apellis Pharmaceuticals, Inc. (APLS) shares rallied 135.4% in the last trading session to close at $40.23. This move can be attributable to notable volume with...
Analyst ratings
54%
of 35 ratingsMore BIIB News
J.P. Morgan analyst Anupam Rama has maintained their neutral stance on APLS stock, giving a Hold rating today. End of Quarter Sale - 50% Off TipRanks Unlock hed...
Stock futures are higher ahead of the open. This follows a difficult month in which the S&P 500 and Nasdaq moved into correction territory and are on track for...
The acquisition is expected to enhance Biogen’s growth portfolio in immunology and rare diseases and add significant value to both companies as they navigate th...
Biotech and Pharma Why This Pharma Stock More Than Doubled Today In this article APLS BIIB SPX Biogen agreed to acquire Apellis Pharmaceuticals for $41 a share,...
Technology Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars Licensing Biogen (BIIB) struck a deal Tuesday to buy Apellis Pharm...
Shares in Apellis Pharmaceuticals (APLS) rocketed over 130% in pre-market trading today after it was bought by peer Biogen (BIIB) for $5.6 billion to expand its...
Biogen is buying Apellis for $5.6 billion in a deal that deepens its investment in the treatment of kidney diseases. Biogen is spending $5.6 billion to buy Ape...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.